Monoclonal Antibody News and Research RSS Feed - Monoclonal Antibody News and Research

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Further Reading
Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

To support a coordinated, innovative approach to the development of an AIDS vaccine, Texas Biomedical Research Institute scientists, together with a multi-institutional coalition of experts from the United States and Europe, have received a grant for $23 million from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. [More]
Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. [More]
Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Inserm Unit U919, directed by Prof. Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis. [More]
Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

A team of researchers from the Institute for Research in Biomedicine and the Swiss biotech company Humabs BioMed SA has identified novel therapeutic monoclonal antibody candidates isolated from Zika-infected patients and new strategies for Zika virus diagnostics. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. [More]
Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity. [More]
Migraine drug has quick onset of action

Migraine drug has quick onset of action

The drug TEV-48125, shown to be effective for chronic migraine in a phase II trial, appears to work within 3 to 7 days of injection, researchers report. [More]
IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. [More]
Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Despite the known toxic effects of chemotherapy on the heart, the majority of women undergoing breast cancer treatment are not getting the recommended follow-up heart scans, according to research presented at the British Cardiovascular Society Conference in Manchester today. [More]
Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway. [More]
Additional drug treatment options to prevent migraine may offer hope to sufferers

Additional drug treatment options to prevent migraine may offer hope to sufferers

Preventing or shortening the duration of migraine attacks - established drug treatment options and those that could shape future therapies were discussed at the Congress of European Academy of Neurology in Copenhagen. [More]
Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago. [More]
DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. [More]
New lab blood test may help identify HELLP syndrome in pregnant women

New lab blood test may help identify HELLP syndrome in pregnant women

A laboratory blood test developed at Johns Hopkins for the diagnosis of a rare genetic red blood cell disorder also shows promise in identifying HELLP syndrome, a life-threatening high blood pressure condition affecting 1 percent of all pregnant women that causes hypertension along with end organ damage, researchers report in the May issue of the journal Experimental Hematology. [More]
New, comprehensive UHPLC-MS workflow solutions provide in-depth biopharmaceutical characterization

New, comprehensive UHPLC-MS workflow solutions provide in-depth biopharmaceutical characterization

Biopharmaceutical companies can now achieve advanced levels of specificity, sensitivity and speed with specialized analytical workflow solutions for the characterization and quantification of proteins. [More]
Mepolizumab has no hint of added benefit in eosinophilic asthma

Mepolizumab has no hint of added benefit in eosinophilic asthma

The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care now examined in an early benefit assessment whether the drug offers an added benefit for patients in comparison with the appropriate comparator therapy. [More]
Advertisement
Advertisement